NEW YORK, June 19, 2018 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP)
(www.oramed.com), a clinical-stage pharmaceutical
company focused on the development of oral drug delivery systems,
announced today that it will be added to the
FTSE Russell Microcap® Index effective at the open of market on
June 25, 2018, as part of the Russell
Indexes annual reconstitution. Membership in the Russell Microcap®
Index, which remains in place for one year, means automatic
inclusion in the applicable growth and value style indexes.
"We are pleased that Oramed has been selected for inclusion
in the Russell Microcap® Index. We believe this increases our
stock's visibility with institutional investors and has the
potential to broaden our shareholder base," stated Nadav Kidron, CEO of Oramed.
The Russell Microcap® Index is one of the most widely used
small cap indexes by institutional investors. Approximately 1,500
securities are included in the Russell Microcap® Index, with market
capitalizations ranging from $30
million to $1.1 billion.
$9 trillion in investor assets are
benchmarked by the Russell U.S. indexes.
For more information on the Russell Microcap® Index
and the Russell U.S. Indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field
of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(PODTM) technology is based on over 30 years of research by top
scientists at Jerusalem's Hadassah
Medical Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801). The
Company completed multiple Phase II clinical trials under an
Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1
analog capsule (ORMD-0901).
For more information, the content of which is not part of
this press release, please
visit www.oramed.com.
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss increasing visibility
for our stock and potentially broadening our shareholder base, as
well as the timing of expected clinical development programs and
clinical trials and FDA submissions or revolutionizing the
treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the use of and weight given
to the Russell Microcap® Index by other indexes
and potential shareholders, the progress, timing, cost, and results
of clinical trials and product development programs; difficulties
or delays in obtaining regulatory approval or patent protection for
our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and
commercialization activities. In addition, the following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress
further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose
knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of
market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in
real settings; our patents may not be sufficient; and final that
products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with
the U.S. Securities and Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Josh Hexter
+1-844-9 ORAMED ext. 2
Email: josh@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-to-be-added-to-russell-microcap-index-300668387.html
SOURCE Oramed Pharmaceuticals Inc.